Significant transcriptional down-regulation of the human MDR1 gene by β-naphthoflavone: A proposed hypothesis linking potent CYP gene induction to MDR1 inhibition

Medical Hypotheses

Volumn 68, Issue 3, 2007, Pages 661-669

  Nwankwo, Joseph O ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ANTINEOPLASTIC AGENT; AURANTIIN; BETA NAPHTHOFLAVONE; BIOCHANIN A; BUTYLATED HYDROXYANISOLE; CELL NUCLEUS RECEPTOR; CHLORPROMAZINE; COUMARIN; CURCUMIN; CYTOCHROME P450; CYTOCHROME P450 1A1; DEOXYCHOLIC ACID; DEXAMETHASONE; DICOUMAROL; DIGOXIN; DOCETAXEL; DOXORUBICIN; ETHOXYQUIN; GENISTEIN; KOLAVIRON; MENADIONE; MULTIDRUG RESISTANCE PROTEIN 1; PLASMID VECTOR; RETINOIC ACID; STEROID; TRABECTEDIN; VERAPAMIL; XENOBIOTIC AGENT;

ARTICLE; BREAST CANCER; CELL STRAIN 3T3; CELL STRAIN CACO 2; CELL STRAIN MCF 7; COLON CARCINOMA; CONCENTRATION (PARAMETERS); DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; GENE ACTIVATION; GENE ACTIVITY; GENE CONSTRUCT; GENE FUNCTION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; HYPOTHESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL SIGNIFICANCE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VECTOR CONTROL;

3T3 CELLS; ANIMALS; BETA-NAPHTHOFLAVONE; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP3A; DOXORUBICIN; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KINETICS; MICE; P-GLYCOPROTEIN; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 33845962662     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.07.042     Document Type: Article

References (42)

1. Lewis D.F.V. Human cytochromes P450 associated with the Phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 10 (2003) 1955-1972
2. Girault I., Rougier N., Chesne C., et al. Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab Disp 33 12 (2005) 1803-1810
3. Lewis D.F., Modi S., and Dickins M. Structure-activity relationships for human cytochrome P450 substrates and inhibitors. Drug Metab Rev 34 1-2 (2002) 69-82
4. Seree E., Villard P.H., Hever A., et al. Modulation of MDR1 and CYP3a expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun 252 (1998) 392-395
5. Schuetz E.G., Schinkel A.H., Relling M.V., and Schuetz J.D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93 (1996) 4001-4005
6. Schuetz E.G., Schuetz J.D., Thompson M.T., Fisher R.A., Madariage J.R., and Strom S.C. Phenotypic variability in induction of P-glycoprotein mRNA by aromatic hydrocarbons in primary human hepatocytes. Mol Carcinogenesis 12 (1995) 61-65
7. Klaassen C.D., and Slitt A.L. Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 6 (2005) 309-328
8. Lampen A., Ebert B., Stumkat L., Jacob J., and Seidel A. Induction of gene expression of xenobiotic metabolism enzymes and ABC-transport proteins by PAH and a reconstituted PAH mixture in human Caco-2 cells. Biochim Biophys Acta 1681 (2004) 38-46
9. Yasuda K., Lan L.B., Sanglard D., Furuya K., Schuetz J.D., and Schuetz E.G. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exptl Therap 303 (2002) 323-332
10. Baron J.M., Goh L.B., Yao D., Wolf C.R., and Friedberg T. Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping. J Pharmacol Exptl Therap 296 (2001) 351-358
11. Lamba J., Strom S., Venkataramanan R., et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Therap 79 (2006) 325-338
12. Cowan K.H., Batist G., Tulpule A., Sinha B.K., and Myers C.E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83 24 (1986) 9328-9332
13. Ivy S.P., Tulpule A., Fairchild C.R., et al. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line. J Biol Chem 263 35 (1988) 19119-19125
14. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34 1-2 (2002) 83-448
15. Honkakoski P., and Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 347 (2000) 321-337
16. Coe K.J., Nelson S.D., Ulrich R.G., et al. Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical ligands and atypical CYP1A inducers. Drug Metab Dispos 34 7 (2006) 1266-1275
17. Wei P., Zhang J., Dowhan D.H., Han Y., and Moore D.D. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J 2 2 (2002) 117-126
18. Nwankwo J.O., Tahnteng J.G., and Emerole G.O. Inhibition of aflatoxin B1genotoxicity in human liver-derived HepG2 cells by kolaviron biflavonoids and molecular mechanisms of action. Eur J Cancer Prev 9 (2000) 351-361
19. Rushmore T.H., and Kong A.N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3 5 (2002) 481-490
20. Sidorova Y.A., Grishanova A.Y., and Lyakhovich V.V. Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett 155 2 (2005) 253-258
21. Rochat B., Kosel M., Boss G., Testa B., Gillet M., and Baumann P. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 56 1 (1998) 15-23
22. Chan H.Y., Wang H., and Leung L.K. The red clover (Trifolium pratense) isoflavone biochanin A modulates the biotransformation pathways of 7, 12-dimethylbenz[a]anthracene. Br J Nutr 90 1 (2003) 87-92
23. Rinaldi A.L., Morse M.A., Fields H.W., et al. Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo[a]pyrene-7R-trans-7,8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res 62 19 (2002) 5451-5456
24. Thapliyal R., and Maru G.B. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 39 6 (2001) 541-547
25. Moon Y.J., Wang X., and Morris M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20 2 (2006) 187-210
26. Walther W., Wendt J., and Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Therapy 4 (1977) 544-552
27. Stein U., Walther W., and Wunderlich V. Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 30A (1994) 1541-1545
28. Nwankwo J.O., Spector A.A., and Domann F.E. A nucleotide insertion in the transcriptional regulatory region of FADS2 gives rise to human fatty acid delta-6-desaturase deficiency. J Lipid Res 44 (2003) 2311-2319
29. Vickers P.J., Dufresne M.J., and Cowan K.H. Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. Mol Endo 3 1 (1989) 157-164
30. Lahmy S., Salmon J.M., and Viallet P. Microspectrofluorometric comparison of benzo(a)pyrene and dibenzo(c,h)acridine metabolism in single living 3T3 fibroblasts. J Histochem Cytochem 35 2 (1987) 197-201
31. Edelmann H.M., Duchek P., Rosenthal F.E., et al. Cmdr1, a chicken P-glycoprotein, confers multidrug resistance and interacts with estradiol. Biol Chem 380 2 (1999) 231-241
32. Barski O.A., Papusha V.Z., Kunkel G.R., and Gabbay K.H. Regulation of aldehyde reductase expression by STAF and CHOP. Genomics 83 1 (2004) 119-129
33. Blumberg B., Sabbagh W., Juguilon H., et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12 (1998) 3195-3205
34. Kliewer S.A., Moore J.T., Wade L., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92 1 (1998) 73-82
35. Forman B.M., Tzameli I., Choi H.S., et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395 (1998) 612-615
36. Dussault I., and Forman B.M. The nuclear receptor PXR: a master regulator of "homeland" defense. Crit Rev Eukary Gene Expr 12 (2002) 53-64
37. Lewis D.F.V., Jacobs M.N., Dickins M., and Lake B.G. Quantitative structure-activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within CYP1, CYP2, CYP3 and CYP4 families. Toxicology 176 (2002) 51-57
38. Xie W., Barwick J.L., Simon C.M., et al. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev 14 (2000) 3014-3023
39. Takara K., Takagi K., Tsujimoto M., Ohnishi N., and Yokoyama T. Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 306 1 (2003) 116-120
40. Synold T.W., Dussault I., and Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7 5 (2001) 584-590
41. Runge D., Kohler C., Kostrubsky V.E., et al. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273 (2000) 333-341
42. Christensen J.G., and LeBlanc G.A. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res 56 (1996) 574-581